A Phase 1 interventional study of PF-08065010 and Placebo in Healthy, sponsored by Pfizer. Recruiting at 1 site in Belgium. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-24.
Sponsored by Pfizer · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to learn about the safety and effects of the study medicine (called PF-08065010) for possible treatment of rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).
This study is seeking participants who are:
Participants in this study will receive PF-08065010 or placebo. A placebo does not have any medicine in it but looks just like the medicine being studied. PF-08065010 or placebo will be given as a shot (in the abdomen, thigh or back of the arms) or as an IV infusion in the arm (given directly into a vein) at the study clinic.
In Part A, participants will take PF-08065010 or placebo only 1 time and will take part in this study for about 5 months. During this time, they will stay at the study clinic for about 9-10 days and will have about 6 more study visits at the study clinic.
Participants in Part B of the study will take PF-08065010 or placebo once a month, for 3 months and will take part in this study for about 7 months. During this time, they will stay at the study clinic for about 4 days each month and will have about 6 more study visits at the study clinic.
During study clinic stays and study visits, urine, blood samples, and physical exams will be done.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dose C - Participants will receive PF-08065010 or placebo.
Drug: PF-08065010 · Drug: Placebo
Optional Japanese Cohort dose to be determined - Participants will receive PF-08065010 or placebo.
Drug: PF-08065010 · Drug: Placebo
Dose A - Participants will receive PF-08065010 or placebo.
Drug: PF-08065010 · Drug: Placebo
Dose E - Participants will receive PF-08065010 or placebo.
Drug: PF-08065010 · Drug: Placebo
Dose G - Participants will receive PF-08065010 or placebo.
Drug: PF-08065010 · Drug: Placebo
Dose D - Participants will receive PF-08065010 or placebo.
Drug: PF-08065010 · Drug: Placebo
Dose B - Participants will receive PF-08065010 or placebo.
Drug: PF-08065010 · Drug: Placebo
Optional Chinese Cohort dose to be determined - Participants will receive PF-08065010 or placebo.
Drug: PF-08065010 · Drug: Placebo
Dose F - Participants will receive PF-08065010 or placebo.
Drug: PF-08065010 · Drug: Placebo
Optional Cohort with dose to be determined - Participants will receive PF-08065010 or placebo.
Drug: PF-08065010 · Drug: Placebo
Optional Cohort with dose to be determined - Participants will receive PF-08065010 or placebo.
Drug: PF-08065010 · Drug: Placebo
Dose F - Participants will receive PF-08065010 or placebo.
Drug: PF-08065010 · Drug: Placebo
Optional Cohort with dose to be determined - Participants will receive PF-08065010 or placebo.
Drug: PF-08065010 · Drug: Placebo
Optional Cohort with dose to be determined - Participants will receive PF-08065010 or placebo.
Drug: PF-08065010 · Drug: Placebo
Experimental Pfizer compound which will be subcutaneous (SC) or intravenous (IV).
Placebo which will be SC or IV
Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Part A
Time frame: Baseline, approximately up to 5 months
Number of Participants With Clinically Significant Laboratory Abnormalities
Part A
Time frame: Baseline, approximately up to 5 months
Number of Participants With Vital Sign Abnormalities
Part A
Time frame: Baseline, approximately up to 5 months
Number of Participants with Change from Baseline in Physical Exam (PE) Parameters
Part A
Time frame: Baseline, approximately up to 5 months
Number of Participants with Change from Baseline in Electrocardiogram (ECG) Parameters
Part A
Time frame: Baseline, approximately up to 5 months
Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Part B
Time frame: Baseline, approximately up to 7 months
Number of Participants With Clinically Significant Laboratory Abnormalities
Part B
Time frame: Baseline, approximately up to 7 months
Number of Participants with Vital Sign Abnormalities
Part B
Time frame: Baseline, approximately up to 7 months
Number of Participants with Change from Baseline in Physical Exam (PE) Parameters
Part B
Time frame: Baseline, approximately up to 7 months
Number of Participants with Change from Baseline in Electrocardiogram (ECG) Parameters
Part B
Time frame: Baseline, approximately up to 7 months
Area Under the Plasma Concentration-time Profile from Time Zero to the Time of Last Quantifiable Concentration (AUClast)
Part A
Time frame: Predose (Day 1), approximately up to 5 months
Area Under the Curve from Time Zero to Extrapolated Infinite Time (AUCinf)
Part A
Time frame: Predose (Day 1), approximately up to 5 months
Maximum Observed Plasma Concentration (Cmax)
Part A
Time frame: Predose (Day 1), approximately up to 5 months
Time to Reach Maximum Observed Plasma Concentration (Tmax)
Part A
Time frame: Predose (Day 1), approximately up to 5 months
Plasma decay half-life (t1/2) is the time measured for the plasma concentration to decrease by one half.
Part A
Time frame: Predose (Day 1), approximately up to 5 months
Area under the serum concentration time profile over the dosing interval of 28 days (AUCtau)
Part B
Time frame: Predose (Day 1), approximately up to 7 months
Maximum Observed Plasma Concentration (Cmax)
Part B
Time frame: Predose (Day 1), approximately up to 7 months
Time to Reach Maximum Observed Plasma Concentration (Tmax)
Part B
Time frame: Predose (Day 1), approximately up to 7 months
Plasma Decay Half-Life (t1/2)
Part B
Time frame: Predose (Day 1), approximately up to 7 months
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Started Apr 2026 (actual). Primary completion is estimated for Sep 2027, 16 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.